Treatment patterns for metastatic Colorectal Cancer (mCRC) patients have changed considerably over the last decade since the introduction of new chemotherapies and targeted biologics. These treatments are often administered in various sequences with limited evidence regarding their cost-effectiveness.
RTI Health Solutions' Rohan Parikh, PhD, Health Outcomes Scientist coauthored a recent study published in the Journal of Managed Care & Specialty Pharmacy that identifies the most commonly used treatment sequences among elderly mCRC patients and conducts a cost-effectiveness evaluation using parameters derived from real-world data.
Researchers developed a probabilistic discrete event simulation model to evaluate the cost-effectiveness of common treatment sequences. The study found that as more treatments or treatment lines were administered, survival was prolonged marginally but with a considerable increase in costs.
The use of real-world data makes the findings more generalizable to the real-world population versus the highly-controlled trial population and helps decision makers understand the cost-effectiveness of commonly used sequences in day-to-day clinical practice. For more detailed results and methods, see Cost effectiveness of treatment sequences of chemotherapies and targeted biologics for elderly metastatic colorectal cancer patients.